SCOLR sale
This article was originally published in The Tan Sheet
Executive Summary
The Redmond, Wash-based biopharmaceutical firm divests its probiotics division to focus on development of its drug delivery business, according to a Jan. 5 announcement. A new company created by Steven Moger, SCOLR's former VP-operations & CFO, made the $2.72 mil. purchase, which will include additional amounts contingent on sales and royalties. SCOLR maintains a positive outlook for 2004. "We continue to work aggressively toward initiating new development agreements with other pharmaceutical and OTC potential partners," President & CEO David Wilds maintains...
You may also be interested in...
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification
Sandoz argued against paying higher rebates for two of its drugs via the Centers for Medicare and Medicaid Services’ Medicaid drug rebate program in a US court six years after the suggestion was first made.